TY - JOUR
T1 - Long-Term Survival Differences Between T1-2 Invasive Lobular Breast Cancer and Corresponding Ductal Carcinoma After Breast-Conserving Surgery
T2 - A Propensity-Scored Matched Longitudinal Cohort Study
AU - Wang, Kang
AU - Zhu, Gui Qi
AU - Shi, Yang
AU - Li, Zhu Yue
AU - Zhang, Xiang
AU - Li, Hong Yuan
N1 - Funding Information:
Supported in part by grants from National Key Clinical Specialty Construction Program of China, Chinese Academy of Medical Sciences & Peking Union Medical College (2014BAI08B03), Zhejiang Province Key Project of Science and Technology (2014BAI08B00).
Funding Information:
Supported in part by grants from National Key Clinical Specialty Construction Program of China, Chinese Academy of Medical Sciences & Peking Union Medical College ( 2014BAI08B03 ), Zhejiang Province Key Project of Science and Technology (2014BAI08B00).
Publisher Copyright:
© 2018 Elsevier Inc.
PY - 2019/2
Y1 - 2019/2
N2 - Background: The role of histology subtype on the prognosis of T1-2 breast cancer patients receiving breast-conserving surgery (BCS) is not clear. Methods: The Surveillance, Epidemiology, and End Results (SEER) Program was used to compare overall survival, second primary cancer-free survival (CFS), and local recurrence risk (LR) for patients with invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC), both receiving BCS. Results: The study enrolled 196,688 patients with T1-2 disease receiving BCS, including 12,906 with ILC and 183,782 with IDC. Patients with IDC showed higher unadjusted annual rates of BCS than ILC. Five- and 10-year estimated survival rates were, respectively, 92.06% and 86.14% in ILC, compared to 90.50% and 85.26% in IDC (P =.12). In multivariable Cox regression, ILC patients showed advantage over IDC in overall survival (hazard ratio [HR] = 0.93, P =.001), whereas no significant differences in CFS (HR = 1.03, P =.33) and LR (HR = 1.17, P =.06) were found, which were consistent with results from matched cohort. In subgroup analyses, patients with grade III ILC had poorer CFS (HR = 1.23, P =.009) and higher LR (HR = 1.59, P =.01) than IDC. Conclusion: Histologic type is of prognostic importance in T1-2 patients receiving BCS, and surgeons should be cautious in performing BCS for individuals with grade III ILC.
AB - Background: The role of histology subtype on the prognosis of T1-2 breast cancer patients receiving breast-conserving surgery (BCS) is not clear. Methods: The Surveillance, Epidemiology, and End Results (SEER) Program was used to compare overall survival, second primary cancer-free survival (CFS), and local recurrence risk (LR) for patients with invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC), both receiving BCS. Results: The study enrolled 196,688 patients with T1-2 disease receiving BCS, including 12,906 with ILC and 183,782 with IDC. Patients with IDC showed higher unadjusted annual rates of BCS than ILC. Five- and 10-year estimated survival rates were, respectively, 92.06% and 86.14% in ILC, compared to 90.50% and 85.26% in IDC (P =.12). In multivariable Cox regression, ILC patients showed advantage over IDC in overall survival (hazard ratio [HR] = 0.93, P =.001), whereas no significant differences in CFS (HR = 1.03, P =.33) and LR (HR = 1.17, P =.06) were found, which were consistent with results from matched cohort. In subgroup analyses, patients with grade III ILC had poorer CFS (HR = 1.23, P =.009) and higher LR (HR = 1.59, P =.01) than IDC. Conclusion: Histologic type is of prognostic importance in T1-2 patients receiving BCS, and surgeons should be cautious in performing BCS for individuals with grade III ILC.
KW - Invasive lobular carcinoma
KW - Local recurrence risk
KW - Overall survival
KW - Second primary cancer-free survival
UR - http://www.scopus.com/inward/record.url?scp=85057230542&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85057230542&partnerID=8YFLogxK
U2 - 10.1016/j.clbc.2018.10.010
DO - 10.1016/j.clbc.2018.10.010
M3 - Article
C2 - 30502219
AN - SCOPUS:85057230542
SN - 1526-8209
VL - 19
SP - e101-e115
JO - Clinical Breast Cancer
JF - Clinical Breast Cancer
IS - 1
ER -